Jakafi 5 mg tablet is a prescription medicine containing Ruxolitinib for oral use, marketed by Incyte, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store JAKAFI/JAKAFI XR at 20°C to 25°C (68°F to 77°F), excursions permitted…
Key facts
- Active ingredient (INN)
- Ruxolitinib
- Brand
- Jakafi
- Strength
- 5 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 60 tablets
- Marketing authorisation holder
- Incyte
- Manufacturer
- Incyte
- Origin register
- US FDA, United States
- Storage
- Store JAKAFI/JAKAFI XR at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F). Protect from light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- D11AH09 Ruxolitinib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 16 November 2011
- Identifiers
- RxCUI 1193331, 1193337, 1193339 +7DailyMed set ID f1c82580-87ae-11e0-bc84-0002a5d5c51bNDC 50881-005Application NDA202192
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 60 tablet in 1 bottle, plastic | 50881-005-60 | Incyte | 16 November 2011 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Ruxolitinib
Clinical summary
Ruxolitinib is a janus kinase inhibitor indicated for treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis in adults, among other approved uses. MedsAcross supplies Ruxolitinib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RuxolitinibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- JAKAFI prescribing information (Incyte) · U.S. National Library of Medicine, DailyMed
- Jakavi: European public assessment report (EPAR) · European Medicines Agency
- Opzelura: European public assessment report (EPAR) · European Medicines Agency
Need Jakafi 5 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.